MDGL
Madrigal Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +6.8% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 121 | +1 | 10.47M | $5.62B | +9 | −9 |
| Q1 2026 | 124 | +7 | 12.07M | $6.32B | +9 | −3 |
| Q4 2025 | 116 | 0 | 12.47M | $7.26B | +1 | — |
| Q3 2025 | 19 | +1 | 6.80M | $3.12B | +1 | −1 |
| Q2 2025 | 16 | 0 | 6.45M | $1.95B | — | — |
| Q1 2025 | 13 | +1 | 2.28M | $753.61M | +1 | — |
| Q4 2024 | 12 | +2 | 2.15M | $662.73M | +2 | — |
| Q3 2024 | 9 | +1 | 1.41M | $299.66M | +3 | −2 |
| Q2 2024 | 8 | — | 1.43M | $401.79M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 1.88M | — | $568.14M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 1.44M | — | $435.42M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 3 | State Street Global Advisors ✦ (passive) | 690.72K | -8.9% | $209.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 508.46K | -6.3% | $153.88M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 5 | Fidelity (FMR) ✦ | 445.34K | — | $134.78M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 6 | Geode Capital Management ✦ (passive) | 414.39K | -1.5% | $125.43M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 7 | Adage Capital Partners ✦ | 376.16K | +96.3% | $113.84M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 207.34K | +25785.0% | $62.75M | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | Norges Bank ✦ (passive) | 176.47K | +87.7% | $53.41M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 111.98K | +13.1% | $33.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Point72 Asset Management ✦ | 110.88K | +68.3% | $33.56M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 12 | Marshall Wace ✦ | 55.12K | +1868.5% | $16.68M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 13 | Renaissance Technologies ✦ | 10.84K | -87.3% | $3.28M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | Millennium Management ✦ | 10.84K | +332.2% | $3.28M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Wellington Management ✦ | 7.38K | -3.3% | $2.23M | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 16 | AQR Capital Management ✦ | 3.17K | -16.0% | $958,461 | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 374 holders, 23.71M shares, $12.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 120 sh · $65,565
Officer, Director · 60 sh · $31,985
Officer, Director · 106 sh · $56,611
Officer, Director · 218 sh · $116,836
Officer, Director · 160 sh · $86,019
Officer, Director · 687 sh · $371,382
Officer, Director · 368 sh · $199,324
Officer, Director · 1.20K sh · $652,209
Officer, Director · 1.54K sh · $837,253
Officer, Director · 761 sh · $414,616
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology